Nebulized Bacteriophage in a Patient With Refractory Lung Disease

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2022 Jul 7

PMID 35794944

Authors

Rebekah M Dedrick

Krista G Freeman

Jan A Nguyen

Asli Bahadirli-Talbott

Mitchell E Cardin

Madison Cristinziano

Bailey E Smith

Soowan Jeong

Elisa H Ignatius

Cheng Ting Lin

Keira A Cohen

Graham F Hatfull

Affiliations

Soon will be listed here.

Abstract

An elderly man with refractory lung disease previously developed anti-phage neutralizing antibodies while receiving intravenous phage therapy. Subsequent phage nebulization resulted in transient weight gain, decreased C-reactive protein, and reduced burden. Weak sputum neutralization may have limited the outcomes, but phage resistance was not a contributing factor.

Citing Articles

The Appearance of Antiphage Antibodies in Sera of Patients Treated with Phages.

Lusiak-Szelachowska M, Weber-Dabrowska B, Zaczek M, Miedzybrodzki R, Gorski A Antibiotics (Basel). 2025; 14(1.

PMID: 39858371 PMC: 11759190. DOI: 10.3390/antibiotics14010087.

Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery.

Smytheman T, Pecor T, Miller D, Ferede D, Kaur S, Harband M Virol J. 2025; 22(1):14.

PMID: 39833928 PMC: 11748884. DOI: 10.1186/s12985-024-02552-2.

Comparative study on the virulence of mycobacteriophages.

Rubino I, Guerrero-Bustamante C, Harrison M, Co S, Tetreau I, Ordoubadi M bioRxiv. 2024; .

PMID: 39554140 PMC: 11565895. DOI: 10.1101/2024.10.23.619922.

Mycobacteriophages and Their Applications.

Bonacorsi A, Ferretti C, Di Luca M, Rindi L Antibiotics (Basel). 2024; 13(10).

PMID: 39452193 PMC: 11504140. DOI: 10.3390/antibiotics13100926.

A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.

Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y Antibiotics (Basel). 2024; 13(9).

PMID: 39335043 PMC: 11428490. DOI: 10.3390/antibiotics13090870.

References

Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S . Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States. Open Forum Infect Dis. 2020; 7(9):ofaa389. PMC: 7519779. DOI: 10.1093/ofid/ofaa389. View

Dedrick R, Smith B, Garlena R, Russell D, Aull H, Mahalingam V . Mycobacterium abscessus Strain Morphotype Determines Phage Susceptibility, the Repertoire of Therapeutically Useful Phages, and Phage Resistance. mBio. 2021; 12(2). PMC: 8092298. DOI: 10.1128/mBio.03431-20. View

Dedrick R, Freeman K, Nguyen J, Bahadirli-Talbott A, Smith B, Wu A . Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med. 2021; 27(8):1357-1361. PMC: 8571776. DOI: 10.1038/s41591-021-01403-9. View

Johansen M, Herrmann J, Kremer L . Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020; 18(7):392-407. DOI: 10.1038/s41579-020-0331-1. View

Leung S, Carrigy N, Vehring R, Finlay W, Morales S, Carter E . Jet nebulization of bacteriophages with different tail morphologies - Structural effects. Int J Pharm. 2018; 554:322-326. DOI: 10.1016/j.ijpharm.2018.11.026. View

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020; 56(1). PMC: 8375621. DOI: 10.1183/13993003.00535-2020. View

Kortright K, Chan B, Koff J, Turner P . Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe. 2019; 25(2):219-232. DOI: 10.1016/j.chom.2019.01.014. View

Hatfull G, Dedrick R, Schooley R . Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med. 2021; 73:197-211. DOI: 10.1146/annurev-med-080219-122208. View

Salmond G, Fineran P . A century of the phage: past, present and future. Nat Rev Microbiol. 2015; 13(12):777-86. DOI: 10.1038/nrmicro3564. View

10.

Carrigy N, Chang R, Leung S, Harrison M, Petrova Z, Pope W . Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. Pharm Res. 2017; 34(10):2084-2096. DOI: 10.1007/s11095-017-2213-4. View

11.

Dedrick R, Guerrero-Bustamante C, Garlena R, Russell D, Ford K, Harris K . Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019; 25(5):730-733. PMC: 6557439. DOI: 10.1038/s41591-019-0437-z. View